Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease



Rating:

Share or cite this content

Citations should be made in the following way:
L. Touqui (Paris, France). Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis. Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease

Member's Comments

No comment yet.

Related content which might interest you: Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002 Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies Source: Eur Respir J 2017; 49(1): 1600903; DOI: 10.1183/13993003.00903-2016 Year: 2017 Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020 Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021 Year: 2022 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Genotype-specific small-molecule therapy for cystic fibrosis Source: Breathe 2013; 9: 176-186 Year: 2013 Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 Role of CF ion transport defect in airway inflammation and implication for antiinflammatory therapies Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012 Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells Source: Eur Respir J 2015; 45: 428-439 Year: 2015